PIERIS PHARMACEUTICALS, INC. Business Operations Contracts & Agreements
29 Contracts & Agreements
- Collaboration Agreements (16 contracts)
- Development Agreements (3)
- Indemnification Agreements (2)
- Management Agreements (4)
- Sales Agreements (1)
- Services Agreements (2)
- Settlement Agreements (1)
- Contingent Value Rights Agreement, dated as of December 13, 2024, by and among, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.), Shareholder Representative... (Filed With SEC on December 16, 2024)
- Second Amendment to Development Funding and Royalties Agreement, dated November 28, 2023, by and between Ligand Pharmaceuticals, Inc. and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)
- First Amendment to Development Funding and Royalties Agreement, dated May 22, 2020, by and between Ligand Pharmaceuticals, Inc. and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)
- Development Funding and Royalties Agreement, dated December 13, 2018, by and between Ligand Pharmaceuticals, Inc. and Palvella Therapeutics, Inc (Filed With SEC on August 9, 2024)
- Form of Indemnification Agreement by and between Palvella Therapeutics, Inc. and certain of its directors (Filed With SEC on August 9, 2024)
- Amendment No. 1, dated September 12, 2023, to the Amended and Restated License and Collaboration Agreementby and between the Registrant and Seagen Inc (Filed With SEC on November 14, 2023)
- Amendment No. 1 to Sales Agreement, dated November 4, 2022, by and between Pieris Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on November 4, 2022)
- Amendment No. 5, dated August 1, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on November 4, 2022)
- Amendment No. 4, dated June 30, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on August 4, 2022)
- Amendment No. 3, dated June 9, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on August 4, 2022)
- Research Collaboration and License Agreement, dated May 19, 2021, by and among Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH and Genentech, Inc (Filed With SEC on August 5, 2021)
- Amendment No. 2, dated March 29, 2021, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on May 17, 2021)
- Amended and Restated License and Collaboration Agreement, dated March 24, 2021, by and between Pieris Pharmaceuticals, Inc. and Seagen Inc (Filed With SEC on May 17, 2021)
- Clinical Trial Collaboration and Supply Agreement, dated August 10, 2020, by and between Pieris Pharmaceuticals, Inc. and Eli Lilly and Company (Filed With SEC on November 4, 2020)
- Amendment No. 1 to the February 8, 2018 License and Collaboration Agreement by and among Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH and Seattle Genetics, Inc (Filed With SEC on August 10, 2020)
- Letter Amendment to the License and Collaboration Agreement by and between Les Laboratoires Servier, Institut de Recherches Internationales Servier, Pieris Pharmaceuticals, Inc.... (Filed With SEC on March 13, 2020)
- Managing Director Services Agreement by and between Pieris Pharmaceuticals GmbH and Hitto Kaufmann, PhD., dated February 20, 2019 (Filed With SEC on November 12, 2019)
- CONFIDENTIAL TREATMENT REQUESTED AMENDMENT 1 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between (Filed With SEC on August 11, 2017)
- CONFIDENTIAL TREATMENT REQUESTED Research Collaboration and License Agreement (Filed With SEC on March 23, 2016)
- CONFIDENTIAL TREATMENT REQUESTED Collaboration Research and Technology Licensing Agreement (Filed With SEC on March 30, 2015)
- CONFIDENTIAL TREATMENT REQUESTED COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 30, 2015)
- Settlement Agreement between (Filed With SEC on December 18, 2014)
- Management Agreement (The Agreement) between (Filed With SEC on December 18, 2014)
- Management Agreement between (Filed With SEC on December 18, 2014)
- AMENDED AND RESTATED MANAGEMENT AGREEMENT between (Filed With SEC on December 18, 2014)
- Management Agreement (the Agreement) between (Filed With SEC on December 18, 2014)
- INDEMNIFICATION AGREEMENT (Filed With SEC on December 18, 2014)
- CONFIDENTIAL TREATMENT REQUESTED Collaboration Research and Technology Licensing Agreement (Filed With SEC on December 18, 2014)
- CONFIDENTIAL TREATMENT REQUESTED COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on December 18, 2014)
